Tests personalized diet feedback for fatty liver disease
Tests personalized diet and lifestyle feedback in adults with fatty liver disease.
Plain-language title generated from the registry record
Registry title: Personalized Dietary Feedback to Reduce Hepatic Steatosis in Patients With MASLD
Key facts
- Where
- Vienna, AustriaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07914829, who can take part
Where in Austria
- Medical University of ViennaVienna, AustriaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University of Vienna
- Trial code
- NCT07914829
- Record updated
- 4 November 2026
- Original description
Metabolic dysfunction-associated steatotic liver disease (MASLD) and combined metabolic dysfunction and alcohol-associated liver disease (MetALD) are common chronic liver diseases associated with metabolic dysfunction and an increased risk of liver-related and cardiovascular complications. Lifestyle modification, particularly dietary changes and increased physical activity, represents a cornerstone of treatment. However, general lifestyle recommendations are often insufficient to achieve sustained improvements.Read full original descriptionShow less
Effect of Personalized Dietary and Lifestyle Feedback on Hepatic Steatosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Prospective, Randomized Controlled Trial
Metabolic dysfunction-associated steatotic liver disease (MASLD) and combined metabolic dysfunction and alcohol-associated liver disease (MetALD) are common chronic liver diseases associated with metabolic dysfunction and an increased risk of liver-related and cardiovascular complications. Lifestyle modification, particularly dietary changes and increased physical activity, represents a cornerstone of treatment. However, general lifestyle recommendations are often insufficient to achieve sustained improvements.
This prospective, randomized controlled trial aims to investigate whether personalized dietary and lifestyle feedback based on a structured questionnaire is more effective in reducing hepatic steatosis than generic lifestyle recommendations.
A total of 174 patients with MASLD or MetALD will be randomized 1:1 to receive either personalized or generic written feedback at baseline and after 2, 4, and 6 months. Changes in hepatic steatosis, assessed by the controlled attenuation parameter (CAP), will be evaluated over a six-month period.
Inclusion: Age 18-80 years; Controlled attenuation parameter (CAP) >248 dB/m; Sufficient German language proficiency to independently complete the questionnaires; Written informed consent to participate in the study.
Exclusion: Initiation or dose modification of GLP-1 receptor agonists or other weight-modifying pharmacological therapies within the previous three months; Planned bariatric surgery during study participation; Other active chronic liver disease; Type 1 diabetes mellitus; Severe or unstable medical condition that, in the investigator's judgment, may interfere with study participation or interpretation of study results; Significant alcohol consumption, defined as ≥50 g/day in women or ≥60 g/day in men; Pregnancy or breastfeeding.